SCHEMBL3904017

SCHEMBL3904017

Cc1ccc(Cl)c(C)c1C(=O)NC(c1ccccc1)C(C)(C)N(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.40
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
UTS2R Q9UKP6 1/20 0.37
HTT P42858 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
MAPT P10636 2/20 0.36
APAF1 O14727 1/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
MCL1 Q07820 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SLC6A9 P48067 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
S1PR3 Q99500 1/20 0.34
ITGB2 P05107 1/20 0.34
ICAM1 P05362 1/20 0.34
ITGAL P20701 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3906111 0.87 UTS2R (0.50) LMNAALDH1A1SMN1; SMN2UTS2RL3MBTL1
SCHEMBL3907148 0.85 SLC6A9 (0.47) LMNAALDH1A1SMN1; SMN2UTS2RL3MBTL1
SCHEMBL3902170 0.84 LMNA (0.44) LMNAALDH1A1SMN1; SMN2UTS2RHTT
SCHEMBL13662320 0.83 LMNA (0.43) LMNAALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL3905654 0.83 LMNA (0.42) LMNAALDH1A1SMN1; SMN2UTS2RHTT
SCHEMBL3905781 0.82 UTS2R (0.50) LMNAALDH1A1SMN1; SMN2UTS2RHTT
SCHEMBL3901504 0.81 LMNA (0.43) LMNAALDH1A1SMN1; SMN2HTTPRSS1
SCHEMBL3906640 0.80 LMNA (0.42) LMNAALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL3236221 0.80 LMNA (0.37) LMNAALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL3903930 0.80 SLC6A9 (0.41) LMNAALDH1A1SMN1; SMN2UTS2RL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 LMNA 4455/4885ALDH1A1 1358/4885SMN1; SMN2 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.